In conclusion, they implicated Spry2 in regulation of TCL1-augmented ERK signaling and B-cell proliferation and suggested Spry2 epigenetic silencing as an aberration contributing to B-cell lymphoma progression. The gene discussed is SPRY2; the disease is B-cell non-Hodgkin lymphoma.